INMB INmune Bio Inc

$INMB & $QUBT collaboration is a very important project. If any progress is made on the Alzheimer's study, I believe there'll be a moonshot within minutes of the PR. Get to work!

$INMB Yes, Martin Shkreli shorted INmune Bio (INMB). Regulators have formally alleged that Shkreli built a short position in INmune Bio during his recent livestreamed trading challenges. Shkreli has publicly targeted the company on social media and his livestreams, laying out an extensive short thesis against INMB's lead Alzheimer's drug candidate, XPro1595. He predicted a 90% crash in the stock price, arguing that the clinical data was weak and that the drug's mechanism (TNF-alpha inhibition) would fail in clinical trials. This specific short position has also caused him legal trouble. In October 2026, the Federal Trade Commission (FTC) and several states filed a motion to hold Shkreli in contempt of court. Regulators argue that his short positions in biotech companies like INMB, Cassava Sciences, and Capricor Therapeutics violate his existing lifetime ban from participating directly or indirectly in the pharmaceutical industry.

$INMB RARE just sold their voucher for 210M, we will be getting a voucher (upon approval) for 4x the companys current value

$INMB Upcoming Catalyst Sept/Early October In August, INMB said it was targeting the UK Marketing Authorization Application for Ebstrocel in Q4 2026. Earlier guidance had been even more specific: by the end of Q3 or early Q4. That makes late September through October a very realistic window. The upcoming regulatory milestones for Ebstrocel™ represent critical value drivers for INmune Bio Inc., with upcoming UK and EU filings validating manufacturing standards and accelerating the transition to a commercial-stage company. Additionally, a potential U.S. FDA rare pediatric disease approval could yield a Priority Review Voucher worth approximately $100 million, providing substantial non-dilutive capital and driving significant stock volatility.

$INMB The Stage 1 engagement represents QCi's first commercial customer in the pharmaceutical and biotechnology market. The agreement also provides options for additional work as INmune Bio advances its clinical development programs. "This is a great example of what practical quantum computing can look like today," said Yuping Huang, Chairman and Chief Executive Officer of QCi. "INmune Bio has a complex scientific problem and a substantial body of clinical and biological data. Our job is to bring new computing capabilities to that problem and see what we can learn. The potential to help researchers make better decisions about future treatments is exciting, and it opens an important new market for QCi."

$INMB where's that Priority Review Voucher ? Now would be a good time to drop that little dumpling.